16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: A clinicopathologic and molecular study of 115 cases

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          CIC-DUX4 gene fusion, resulting from either a t(4;19) or t(10;19) translocation, is the most common genetic abnormality detected in EWSR1-negative small blue round cell tumors (SBRCTs). Following their discovery it was debated if these tumors should be classified as variants of Ewing sarcoma (i.e. atypical Ewing sarcoma) or as a stand-alone pathologic entity. As such the WHO classification temporarily grouped the CIC-rearranged tumors under undifferentiated sarcomas with round cell phenotype, until further clinical evidence was available. However, most studies reported so far include small series with limited follow-up information which preclude a more definitive assessment. The present work investigates the clinicopathologic features of a large cohort of sarcomas with CIC gene rearrangement, in order to define their clinical presentation, morphologic spectrum, and outcome. Our study further examines the overall survival of the CIC-positive cohort compared to a control group of EWSR1-rearranged Ewing sarcoma matched for age and stage. The study cohort included 115 patients, with a mean age of 32 years and a slight male predominance. Most tumors occurred in the soft tissue (86%), predominantly deep-seated and equally divided among trunk and extremity, followed by visceral locations (12%) and rarely in the bone (3%). Microscopically, most tumors showed round to ovoid cytomorphology but half of the cases showed also focal areas of spindling and epithelioid/rhabdoid phenotype, with frequent myxoid stromal changes. Variable CD99 reactivity was seen in 84% cases, with a diffuse pattern only in 23% of cases, while nuclear WT1 was seen in 92%. A CIC-DUX4 fusion was detected in 57% of cases, with either DUX4 on 4q35 (35%) or on 10q26 in 25 (22%) cases. No FOXO4 gene rearrangements were present in 39 cases tested. Clinical follow-up was available in 57 patients, with a 5-year survival of 43%, which was significantly lower than the 77% 5-year survival in the control Ewing sarcoma group (p=0.002). Our findings show that CIC-DUX4 sarcomas occur most commonly in young adults within the somatic soft tissues, having a wide spectrum of morphology including round, epithelioid and spindle cells, and associated with an aggressive clinical course, with an inferior overall survival compared to Ewing sarcoma. The results support the classification of CIC-rearranged tumors as an independent molecular and clinical subset of SBRCTs distinct from Ewing sarcoma.

          Related collections

          Author and article information

          Journal
          7707904
          470
          Am J Surg Pathol
          Am. J. Surg. Pathol.
          The American journal of surgical pathology
          0147-5185
          1532-0979
          18 March 2017
          July 2017
          01 July 2018
          : 41
          : 7
          : 941-949
          Affiliations
          [1 ]Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
          [2 ]Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
          [3 ]Erciyes University Department of Pathology; Kayseri, Turkey
          [4 ]Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
          [5 ]Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan
          [6 ]Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
          [7 ]Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
          Author notes
          [* ] Corresponding Author: Cristina R Antonescu, MD, Memorial Sloan Kettering Cancer Center, Department of Pathology, 1275 York Ave, New York, NY, Phone: (212) 639-5905; antonesc@ 123456mskcc.org
          Article
          PMC5468475 PMC5468475 5468475 nihpa853509
          10.1097/PAS.0000000000000846
          5468475
          28346326
          eaf1c7e2-12a9-4784-a189-8f54b313130b
          History
          Categories
          Article

          CIC,DUX4,SBRCT,round cell sarcoma
          CIC, DUX4, SBRCT, round cell sarcoma

          Comments

          Comment on this article